
Opinion|Videos|August 27, 2024
Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease
Key opinion leaders examine the comparative safety profiles and response durations of combination therapy versus monotherapy in the treatment of BCG-unresponsive carcinoma in situ with or without papillary disease.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Did safety outcomes with combination therapy vary from those observed with monotherapy cretostimogene or pembrolizumab?
- Can you please talk about the duration of response and how this compares to other agents that have been tested in BCG UR CIS +/- papillary disease?
Advertisement
Related to this article

Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.

Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.

CG Oncology plans to submit a second biologics license application to the FDA for cretostimogene in BCG-unresponsive NMIBC by the end of March 2027

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
Advertisement
Advertisement
Trending on Urology Times
1
LIB-01 enters phase 2b development for erectile dysfunction
2
Jonathan Rosenberg, MD, reacts to FDA approval of durvalumab plus EV for MIBC
3
Treatment Targets, Formulations, and the Future of Testosterone
4
Rethinking Testosterone Therapy After the FDA Label Revisions
5



